{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.1","upperLimit":"23.6","value":"19.1"},{"groupId":"OG001","lowerLimit":"49.1","upperLimit":"57.0","value":"53.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"181"}],"units":"Participants"}],"description":"DOR was defined as the time from first occurrence of a documented response of CR, CRi, nPR, or PR until PD/relapse, as assessed by the investigator according to the iwCLL guidelines, or death from any cause. PD: occurrence of one of the following: new lesion; new palpable lymph node (\\>1.5 cm); unequivocal progression of non-target lesion; increase of \\>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \\>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \\>/=50% in platelet or neutrophil count, or hemoglobin level by \\>2 g/dL or to \\<10 g/dL. Participants without PD or death after response were censored at the last date of adequate response assessment. The median DOR was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bendamustine at a dose of 70 milligrams per meter square (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Bendamustine + Rituximab Main Study"},{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG001","title":"Venetoclax + Rituximab Main Study"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on ITT population participants who had best overall response of CR, CRi, nPR, or PR.","reportingStatus":"POSTED","timeFrame":"From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)","title":"Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines","type":"SECONDARY","unitOfMeasure":"months"}